“…Transdermal scopolamine has been dem onstrated to provide significant protection against mo tion sickness, both under laboratory conditions of con trolled motion [Graybiel et al, 1976[Graybiel et al, , 1982, and at sea [Price et al, 1981;Van Marion et al, 1985], Current models of motion sickness place primary emphasis upon muscarinic acetylcholine neurotransmis sion, which is hypothesised to underly the transmission of motion information from the vestibular organs, to the brainstem areas subserving vomiting Reason and Brand, 1975]. Acetylcholine is also important for psychological functions such as sustained attention, vigilance, stimulus processing, and memory storage [Deutsch, 1971;Warburton, 1975;Warburton and Wesnes, 1984]; these functions are significantly im paired by oral or parenteral scopolamine [Colquohoun et al, 1962; Ghoneim and Mewaldt, 1975;Lukomskya and Nikolskay, 1971;Parrott, 1986; Peterson, 1977; Warburton. 1983, 1984).…”